key: cord-0740911-8szq4181
authors: Holmqvist, Jacob; Beck‐Friis, Josefine; Jensen, Carl; Dalla, Keti; Mårdstam, Simon; Christensen, Jens; Nordén, Nina; Widing, Hannes; Rosén‐Wetterholm, Elin; Cavefors, Oscar; Yilmaz, Aylin; Cronhjort, Maria; Redfors, Björn; Oras, Jonatan
title: Cardiac dysfunction and mortality in critically ill patients with COVID‐19: A Swedish multicentre observational study
date: 2022-02-13
journal: Acta Anaesthesiol Scand
DOI: 10.1111/aas.14039
sha: a317eb4f6d73b010eb45d1c6529bd9cb957ddea4
doc_id: 740911
cord_uid: 8szq4181

BACKGROUND: The prevalence and importance of cardiac dysfunction in critically ill patients with COVID‐19 in Sweden is not yet established. The aim of the study was to assess the prevalence of cardiac dysfunction and elevated pulmonary artery pressure (PAP), and its influence on mortality in patients with COVID‐19 in intensive care in Sweden. METHODS: This was a multicentre observational study performed in five intensive care units (ICUs) in Sweden. Patients admitted to participating ICU with COVID‐19 were examined with echocardiography within 72 h from admission and again after 4 to 7 days. Cardiac dysfunction was defined as left ventricular (LV) dysfunction (ejection fraction <50% and/or regional hypokinesia) or right ventricular (RV) dysfunction (defined as TAPSE <17 mm or visually assessed moderate/severe RV dysfunction). RESULTS: We included 132 patients, of whom 127 (96%) were intubated. Cardiac dysfunction was found in 42 (32%) patients. Most patients had cardiac dysfunction at the first assessment (n = 35) while a few developed cardiac dysfunction later (n = 7) and some changed type of dysfunction (n = 3). LV dysfunction was found in 21 and RV dysfunction in 19 patients, while 5 patients had combined dysfunction. Elevated PAP was found in 34 patients (26%) and was more common in patients with RV dysfunction. RV dysfunction and elevated PAP were independently associated with an increased risk of death (OR 3.98, p = .013 and OR 3.88, p = .007, respectively). CONCLUSIONS: Cardiac dysfunction occurs commonly in critically ill patients with COVID‐19 in Sweden. RV dysfunction and elevated PAP are associated with an increased risk of death.

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical characteristics of COVID-19 range from asymptomatic infection to critical illness with acute respiratory distress syndrome, shock or multiorgan dysfunction, affecting around 5% of symptomatic cases. 1, 2 Cardiac and thrombotic complications are common in patients with COVID-19 and are associated with a higher mortality and more complicated disease course. 3 Myocardial injury with elevated troponin or creatine kinase is reported in 12 to 38% of hospitalised patients with COVID- 19 4,5 and in approximately 50% of patients treated in intensive care units (ICU). 5, 6 Other cardiac manifestations include myocarditis, 7, 8 Takotsubo cardiomyopathy 9,10 and cardiac dysfunction related to multisystem inflammatory syndrome in children and adults (MIS-C/A). 11, 12 Several studies have reported abnormalities in heart function in a large proportion of patients with COVID-19 undergoing echocardiography 10, 13, 14 and both left-and right ventricular dysfunction seem to be independently correlated to mortality in patients with COVID-19. 13, [15] [16] [17] However, incidence and influence on mortality of cardiac complications in critically ill patients with COVID-19 in Sweden are not sufficiently studied.

The aim of the present study was to assess the incidence of COVID-19-associated cardiac dysfunction and its influence on mortality in critically ill patients with COVID-19 in Sweden.

This was a multicentre observational study. It was approved by the Swedish Ethics Review Authority Sweden (approval number 036-18, 2020-01684 and 2020-03815) and registered in the international database at Clinicaltrials.gov (registration number NCT04524234).

The study was performed in five ICUs in Sweden from 20 April to 30 August 2020. Most patients were included prospectively (n = 98, 72%), but 30 patients were included retrospectively from one of the five study sites. This site followed the study protocol as to both examination with echocardiography and collection of laboratory data on clinical grounds but were not formally participating in the study until after the third ethical approval. Another nine patients were retrospectively included from the other centres, where the study protocol was initiated on clinical grounds before the ethical approval.

Details of each participating ICU are described under Data S1.

All patients ≥18 years of age who were admitted to a participating ICU with verified COVID-19 were eligible for inclusion. Patients were included consecutively when study personnel and resources were available. Echocardiography was performed within 72 h from admission to the ICU and repeated in 4 to 7 days or at clinical deterioration. Cardiac biomarkers, routine laboratory tests and clinical data were recorded at each examination. Consent to study inclusion was obtained from the patient or patient's next of kin whenever possible but waived for those included retrospectively.

Transthoracic echocardiography was performed according to a standardised protocol (see Data S1) for assessment of left RV dysfunction in 19 patients, while 5 patients had combined dysfunction. Elevated PAP was found in 34 patients (26%) and was more common in patients with RV dysfunction. RV dysfunction and elevated PAP were independently associated with an increased risk of death (OR 3.98, p = .013 and OR 3.88, p = .007, respectively). 

Cardiac dysfunction in COVID-19 patients has been reported widely. Here, the authors show that incidence in a Swedish population is comparable to previously reported non-Scandinavian incidences. Especially elevated pulmonary artery pressure and right heart dysfunction showed elevated mortality, while left ventricular dysfunction did not. ventricular (LV) or right ventricular (RV) dysfunction and estimation of pulmonary artery pressure (PAP). LV dysfunction was defined as ejection fraction <50% with or without regional hypokinesia. LV ejection fraction (EF) was assessed with Simpson biplane or with eyeballing. Regional wall motion abnormalities (RWMA) were assessed using the standard 17-segment model. 18 RV dysfunction was defined as a tricuspid annular plane systolic excursion (TAPSE) <17 mm, or visually assessed at least moderately depressed RV dysfunction. In patients with a tricuspid regurgitation (TR), elevated PAP was defined as TR jet velocity >2.9 m/s (TR Vmax). In patients with no tricuspid regurgitation, we defined elevated PAP through indirect criteria combining the following Systolic blood pressure, mean arterial pressure, diastolic blood pressure, vasopressor dosage, lactate levels, ventilator settings and PaO2/ FiO2-ratio were recorded when echocardiography was performed.

Mortality at 30 days and death occurring within 90 days of admission to the ICU were registered.

The predefined primary outcome was 30-day mortality in patients with versus without cardiac dysfunction on admission to the ICU. Subgroup analysis was performed for LV and RV dysfunction. 

A statistical analysis plan was written before the analyses were performed (Data S1). Normally distributed variables are presented as mean ± standard deviation; non-normally distributed variables are presented as median and interquartile range (IQR). Student´s t-test was used to compare means of normally distributed variables and the Mann-Whitney U test was used for comparison of distributions of non-normally distributed variables. Fisher's exact test was used for comparison of binary outcomes between two groups. Logistic regression was used to evaluate mortality at 30 days between patients with or without cardiac dysfunction in a non-adjusted and a risk-adjusted analysis (primary outcome). Kaplan-Meier methodology with a log rank test was used to compare incidences over time. IBM SPSS Statistics Version 26 was used for the statistical analyses. No power analysis was performed, as insufficient data of the study population were available when the study was initiated, but we aimed for inclusion of at least 100 patients.

In total, 234 patients were admitted to each participating centre during their study periods, of whom 137 were included in the study.

Inclusion failure occurred when no investigator involved in the study was available for including patients or performing echocardiographic examination. In a sensitivity analysis regarding SAPS score, age and 30-days mortality, the study population was representative of each ICU´s patient population. 22 Two patients were excluded due to their echocardiography being performed >72 h from admission. An additional three patients were excluded because of poor echocardiographic image quality. Thus, a total of 132 patients included in the final analysis ( Figure 1 ).

The median age of the cohort was 63 years (IQR 53-70); 34 (26%) were women. Median body mass index (BMI) was 30 (IQR [25] [26] [27] [28] [29] [30] [31] [32] [33] . (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) .577

Risk score SAPS3 51 ± 9 51 ± 9 53 ± 10 .285

Medical history Any cardiac disease, n (%) 17 (13) 8 (9) 9 (21) .055

Heart failure, n (%) 0 (0) 0 (0) 0 (0) -Coronary artery disease, n (%) 15 (11) 8 (9) 7 (17) .240

Atrial fibrillation, n (%) 5 (4) 2 (2) 3 (7) .326

.100

Other cardiac disease, n (%) 1 (1) 0 (0) 1 (2) .318

Cerebrovascular disease, n (%) 10 (8) 5 (6) 5 (12) .288

COPD or astma, n (%) 13 (10) 9 (10) 4 (10) >.999

Renal failure, n (%) 7 (5) 4 (4) 3 (7) .679

Any risk factor of CVD, n (%) 74 (56) 44 (49) 30 (71) .023

Diabetes, n (%) 29 (22) 19 (21) 10 (24) .822

Hypertension, n (%) 58 (44) 32 (36) 26 (62) .005

Hyperlipidaemia, n (%) 25 (19) 13 (14) 12 (29) .061

Other, n (%) 28 (21) 18 (20) 10 ( (20) 22 (23) 5 (14) PCV, n (%) 17 (13) 9 (9) 8 (23) APRV, n (%) 13 (10) 9 (9) 4 (11)

High flow oxygen, n (%) 12 (9) 9 (9) 3 (9) 

In total, 24 patients (18%) died within 30 days of admission to the ICU.

The difference in 30-day mortality between patients with cardiac dysfunction (n = 10, 24%) and with normal cardiac function (n = 14, 16%)

was not significant (p = .332). There was no increased risk of death at 

The main findings of this study are that (1) of radial RV dysfunction. This is not an objective method and using e.g.

fractional area change would yield a higher reproducibility and possibly identification of more RV pathology. 23 In addition, not all centres calculated Simpson biplane routinely. Furthermore, we did not register fluid balance which is a potential confounder in the assessment of RV and LV function. Other limitations are that not all eligible patients were included due to a lack of study resources, that not all patients had a follow-up echocardiography and that the time frames for this follow-up were wider than desired. However, patients were included systematically when resources were available, and a sensitivity analysis shows that the study population was a representative sample of each site´s total COVID-19 population. The main strengths of the study are the multi-centre design, giving a presumably high generalisability of severe COVID-19 in Sweden, and that echocardiographic follow-up was performed in a majority of patients, which is not performed in most studies of COVID-19 associated cardiac dysfunction.

In our study, 32% of the patients had cardiac dysfunction de- LV ejection fraction, % 59 ± 5 43 ± 6 * 57 ± 11

Stroke volume indexed, ml/m 2 40 ± 12 30 ± 9 * 37 ± 11

Cardiac index, L/min/m 2 3.1 ± 0.9 2.4 ± 1 * 3.0 ± 1

Regional hypokinesia, n (%) Note TR Vmax is reported from patients with a TR present. In the group normal cardiac function, data are reported for first echo. In the groups LV or RV dysfunction, data are reported from the first echo when dysfunction is detected.

Abbreviations: LV, left ventricle; PAP, pulmonary arterial pressure; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; TR Vmax, maximal tricuspid regurgitation velocity. a Includes patients with combined dysfunction.

*p-value < .05 vs group of normal cardiac function. One of the main findings in this study was the high prevalence of elevated PAP, which was seen in almost one-third of all patients, correlating closely with RV dysfunction. Both pulmonary embolism and pulmonary microangiopathy with microthrombosis are common in severe cases of COVID-19 and are known causes of elevated PAP. [28] [29] [30] Furthermore, RV failure is a complication to ARDS, which has been recognised since before SARS-CoV-2 emerged. 31 Both RV dysfunction and elevated PAP were associated with an increased risk of death. This is consistent with several previous publications of COVID-patients, including two meta-analyses and one Scandinavian study. 15, 24, 27 It is likely that RV dysfunction is secondary to elevated PAP in most cases and that this reflects a higher degree of pulmonary disease. It could therefore be of value to investigate patients with RV dysfunction or elevated PAP further by computer tomography for diagnosis of pulmonary embolism, worsening of ARDS, COVID-19 typical infiltrates or secondary bacterial infection. Furthermore, pulmonary vasodilators could be tried to see if there is improvement in RV function or decreased PAP. 32 Notably, LV dysfunction was not associated with an increased risk of death. We identified a number of different types and causes of LV dysfunction including COVID-19 myocarditis, Takotsubo syndrome and MIS-C, all described previously in COVID-19. 9,10,33 In most cases, we were not able to classify the cause of LV dysfunction but other plausible causes of LV dysfunction are secondary effects due to hypoxia, hypotension or a toxic effect due to the inflammatory state. 34 Previous studies have shown conflicting results regarding LV dysfunction and death, and it is likely that LV dysfunction is of less importance compared with RV dysfunction in severe COVID-19. 25, 35 In conclusion, cardiac dysfunction is common in critically ill Swedish patients with COVID-19 on admission to ICU, and RV dysfunction and elevated PAP are associated with an increased risk of death. We suggest that echocardiography, with focus on RV function and PAP, should be performed in COVID-19 patients on admission to the ICU. However, further research is needed to assess and establish a causal relationship between RV dysfunction and death and how to best treat this condition.

None.

Heart-Lung foundation for the conduct of this study. The other authors declare that they have no competing interests. 

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese center for disease control and prevention

Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review

Cardiac injury in COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Acute cardiac injury in coronavirus disease 2019 and other viral infections-A systematic review and meta-analysis

Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study

cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China

Typical takotsubo syndrome triggered by SARS-CoV-2 infection

Global evaluation of echocardiography in patients with COVID-19

Multisystem inflammatory syndrome in U.S. children and adolescents

Clinical characteristics of multisystem inflammatory syndrome in adults: a systematic review

Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study

Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study

Association between right ventricular dysfunction and mortality in COVID-19 patients: A systematic review and meta-analysis

Advanced echocardiographic phenotyping of critically ill patients with coronavirus-19 sepsis: a prospective cohort study

D-dimer and right ventricular abnormalities as prognostic factors in critically ill COVID-19 patients

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for european paediatric and congenital cardiology (AEPC), International society for heart and lung transplantation (ISHLT)

Assessment of pulmonary artery pressure by echocardiography-A comprehensive review. IJC Heart and Vasculature

SAPS 3-From evaluation of the patient to evaluation of the intensive care unit. Part 1: objectives, methods and cohort description

April 1) Data portal for The Swedish Intensive Care Registry

Right ventricular dysfunction in critically ill COVID-19 ARDS

Prevalence of right ventricular dysfunction and impact on all-cause death in hospitalized patients with COVID-19: a systematic review and meta-analysis

Echocardiographic Findings in Patients With COVID-19 Pneumonia

Impact of right ventricular dysfunction on mortality in patients hospitalized with COVID-19, according to race

Acute pulmonary hypertension and short-term outcomes in severe Covid-19 patients needing intensive care

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Incidence of acute pulmonary embolism in COVID-19 patients: systematic review and meta-analysis

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients

Acute cor pulmonale in ARDS

Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review

COVID-19 and multisystem inflammatory syndrome in children and adolescents

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Swollen heart in COVID-19 patients who progress to critical illness: a perspective from echo-cardiologists